Medtech company Implantica AG (Nasdaq First North Premier Growth Market:IMP A SDB) on Thursday announced the publication of a real-world study evaluating its RefluxStop device for the treatment of gastroesophageal reflux disease (GERD).

The study, conducted by Priv.-Doz. Dr. Thorsten G. Lehmann, assessed 79 patients at a leading German reflux centre.

Results published in the journal Surgery Open Science demonstrated significant improvements in both proton pump inhibitor (PPI) use and quality of life, even in patients with complex conditions, with median improvements in GERD-HRQL (Gastro-Esophageal Reflux Disease – Health-Related Quality-of-Life) score of 100% and mean improvements of 92.4%.

These findings further support the safety and efficacy of RefluxStop in treating GERD.